Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

CHICAGO and FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced the completion of patient enrollment in the ongoing Phase 2 trial of FOLFIRINOX in combination with elraglusib and losartan for untreated metastatic pancreatic adenocarcinoma (mPDAC). The trial is being led by Colin Weekes MD PhD at Massachusetts General Hospital and is supported by the Lustgarten Foundation as well as Actuate Therapeutics. Additional sites participating in the study include The University of Colorado (led by Cristopher Lieu, MD) and the University of Washington’s Fred Hutchinson Cancer Center (led by Andrew Coveler, MD).

Read more at globenewswire.com